Hims & Hers Health
Valuation each multiple against its own 5-year range
Vs. peers Drug Manufacturers - Specialty & Generic
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Hims & Hers Health (HIMS) | 3.42B | -17.59 | 9.63 | 0.00% |
| Takeda Pharmaceutical (TAK) | 69.76B | 311.00 | 1.50 | 1.44% |
| Teva Pharmaceutical Industries (TEVA) | 45.77B | 91.23 | 5.74 | 0.00% |
| Haleon (HLN) | 39.76B | 19.14 | 1.85 | 2.09% |
| Zoetis (ZTS) | 32.14B | 13.34 | 9.73 | 2.64% |
| United Therapeutics (UTHR) | 23.63B | 20.94 | 3.76 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 57.5% below Morningstar's fair value estimate.
Analyst note
Hims & Hers delivered 49% and 5% growth in revenue and adjusted EBITDA, respectively, during the third fiscal quarter. Full-year guidance was lowered 2% for revenue and 11% for adjusted EBITDA, at the midpoints. Shares traded down 2% afterhours.
Why it matters: We were disappointed by several aspects of the quarter. Although the subscriber count rose 13% year over year, it fell sequentially for the first time in five years. Adjusted EBITDA margin also fell nearly 400 basis points. The subscriber count dynamic is concerning because Hims is expanding its international presence, which should unlock new markets and customers. We think the sequential decline suggests Hims' share in the core US market may be weakening. Management noted some pullback in advertising spending ahead of a larger marketing push in early 2027, which contributed to the softness. EBITDA continues to face headwinds from a mix shift toward lower-margin branded weight-loss offerings. Management also called out more aggressive pricing in some European markets, a new development this quarter. We had anticipated near-term margin pressure from international expansion as the platform scales, but increased pricing competition is an unexpected headwind. This adds to our concerns and introduces further uncertainty around the firm's long-term sustainable margin profile.
The bottom line: We maintain our $23 fair value estimate for no-moat Hims, as recent cash flows offset the impact of lower near-term assumptions. The guidance update is concerning for two reasons. First, Hims has never lowered its revenue guidance in the past three years, so the pullback could signal that growth deceleration could be more pronounced than investors previously thought. Second, EBITDA margin is now expected to reach just 8.5%, down from the 12% originally guided at the end of last year, following sequential declines in every quarter of 2026.
Hims has made several key strategic decisions in recent quarters that have weighed on near-term profitability in pursuit of long-term margin upside. But persistent weakness in today's margin puts more pressure on management to show these investments can ultimately deliver their targeted returns and sustain investor confidence. We highlight our Very High Uncertainty Rating on the name, as we see many risks related to the firm's future cash flow.
On Nov. 6, Hims announced an agreement with Eli Lilly to start offering Zepbound and Foundayo, two of Lilly's weight-loss drugs, on the Hims platform. This looks like a very similar arrangement Hims has with Novo Nordisk. We think this is yet another testament that the firm is doubling down on its weight-loss portfolio strategy, stepping away from compounded products and leaning more into US Food and Drug Administration-approved products, which it has already been doing since its partnership with Novo.
For more information on our long-term outlook on Hims, please see our October 2026 research paper, 'Hims & Hers: Real Peptide Opportunity, but Oversize Price Tag.'
Fair value
We maintain our $23 per share fair value estimate for no-moat Hims. Our 2026 estimates of 33% revenue growth and 8% adjusted EBITDA margin sit on the low end of the guidance and reflect 10% subscriber growth, 20% monthly revenue per subscriber growth, and increased expenses to support a continued international push.
Over our 10-year forecast, we expect low-teens compound annual top-line growth and substantial margin expansion. We model subscribers to grow from 2.5 million at the end of 2025 to about 4 million by 2035, driving much of the revenue tailwind. As patients increasingly seek convenient, personalized healthcare, the broad-based telehealth space should benefit from secular tailwinds. We think Hims should maintain a healthy market share thanks to the brand equity and trust the firm built in recent years, supporting retention and attracting new customers.
That being said, our forecast falls short of management’s long-term targets. In May 2025, Hims announced 2030 guidance of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA, implying a six-year revenue CAGR of 28% and margins rising from 12% in 2024 to 20%. By contrast, our model assumes $5 billion in revenue and roughly $800 million in adjusted EBITDA, or a margin of 16%. While we think the margin target is achievable by 2032, we are conservative on revenue, citing the challenges of maintaining double-digit growth at scale, competitive pressures, and uncertainty around new specialties.
We expect operating leverage from subscriber growth, improved cost management as new facilities scale, and stronger cross-selling. Recent acquisitions in 2024–25 expanded Hims’ manufacturing footprint, which should enhance gross margin through increased capacity and lower per-unit costs. On operating expenses, we model customer acquisition and marketing spending as a percentage of sales declining as subscriber growth drives more organic interest through brand recognition and word-of-mouth.
Economic moat
We assign Hims & Hers a no-moat Morningstar Economic Moat Rating because we do not believe the firm possesses any structural advantages sufficient to generate excess returns over the next 10 years.
Hims operates primarily on a subscription model, offering treatments in areas such as sexual health, hair loss, mental health, and weight loss. Customers select a condition and, if necessary, consult with healthcare professionals before starting treatment. The company’s portfolio consists largely of off-patent pharmaceuticals fulfilled through affiliated pharmacies, often in customized dosages designed to meet individual needs and reduce side effects. As of August 2025, the platform counts roughly 2.5 million subscribers, with more than 60% using at least one personalized solution. While Hims does not disclose subscriber retention, we estimate it at 65%-85%, with patients using personalized solutions at the higher end of the range.
Since going public in January 2021, Hims has delivered rapid growth, expanding from 290,000 subscribers at year-end 2020 to over 2.5 million by year-end 2025. Growth was fueled by rising demand for GLP-1s, strong marketing—including a 2025 Super Bowl ad—and increasing brand visibility across social media and word-of-mouth. These drivers not only supported subscriber growth but also helped the company achieve positive EBITDA, with adjusted margins improving from negative 5.5% in 2020 to 13.5% in 2025.
Despite this strong trajectory, we do not see evidence that Hims possesses a structural competitive advantage that warrants a moat rating. Barriers to entry in telehealth remain low, and new entrants can replicate Hims’ offerings with relative ease.
Reviewing Hims’ portfolio, we don’t see signs of revolutionary or meaningfully different products that a patient can only get from the platform and not from competing players. For instance, Hims’ hair care offerings largely repackage finasteride and minoxidil—off-patent ingredients found in Propecia and Rogaine—and various supplements. While Hims tries to differentiate itself by offering a mixed combination of these active ingredients and in different forms like chewables, topical sprays, and topical serums, we don’t see any material efficacy differences between Hims’ products and over-the-counter products. Furthermore, competing telehealth firms like Ro and Keeps also offer their own versions of finasteride/minoxidil combinations in similar, if not the same, dosages and forms, leaving patients with a variety of options. We think this curbs potential pricing power that Hims can attain over peers despite its brand presence, and our analysis is substantiated by the fact that near-identical products from Ro and Keeps carry similar prices. We reach a similar conclusion in categories such as sexual health and weight loss, where Hims’ offerings are not meaningfully distinct from peers.
We concede that Hims’ returns on invested capital over the past three years look impressive, which could potentially point to signs of a moat, at least from a purely quantitative standpoint. The firm consistently generated an adjusted ROIC above 30% from 2022 to 2025, far exceeding our assumed weighted average cost of capital of 9%. However, we believe this paints an irregular and temporary picture as the firm benefited from unique tailwinds, including pandemic-driven adoption of virtual care in 2021 and a branded semaglutide shortage in 2024.
Looking ahead, we think these dynamics are unlikely to persist and expect both subscriber growth and ROIC to moderate as the base expands and competition intensifies. While Hims has looked to support growth via international expansion and new specialty entries, we don’t fully buy into the idea that these initiatives will provide a meaningful competitive advantage. We believe that Europe’s differing healthcare systems and regulatory hurdles could prove challenging to simply copy and paste the US model, and new specialties like hormone therapy and menopause care are not challenging for a peer to replicate. As a result, we expect ROIC to trend downward starting in 2025, reaching around 10% by our midcycle year.
Bull case
An increasing shift to digital healthcare underpins long-term growth potential for Hims’ subscribers.
Hims targets one to two new specialty entries every year. With a proven track record of cross-selling across its subscribers, new therapies should offer further growth opportunities.
Geographic expansion into markets like Western Europe widens Hims’ total addressable market, and management can apply findings from the US market to effectively target and win new subscribers.
Bear case
Failure to optimize customer acquisition costs could weigh down subscriber growth and put pressure on margin, two figures crucial to Hims’ long-term targets.
Geographic expansion has come with significant margin pressure, both from higher operating costs and unfavorable pricing dynamics, and it could undermine the return on investments for both the Zava and Eucalyptus acquisitions.
Barriers to entry in the telehealth space are low, and newcomers as well as existing players could steal future patients and limit Hims’ long-term growth potential.
By Keonhee Kim
Quote time 2026-11-20 20:02:17 · For reference only, not investment advice and not tailored to your situation.
Hims & Hers Health discussion 0 comments